Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.
The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies of OCE-205 in refractory ascites next year.
Researchers have developed a novel chronic lymphocytic leukemia (CLL) murine model that expresses human BCL2 in B cells under the TCL1 promoter control, named TBC.
In a study published in Antiviral Research, researchers from the Max Planck Institute for Multidisciplinary Sciences and collaborators have presented optimized nanobodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
Iama Therapeutics Srl has obtained clinical trial application (CTA) clearance from the Italian Medicines Agency (AIFA) to initiate a first-in-human phase I study of IAMA-6, an orally administered small-molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.
Researchers from Johns Hopkins University and affiliated organizations have published details on the discovery and preclinical characterization of a purine antimetabolite, Pro-905, which is being developed for the treatment of malignant peripheral nerve sheath tumors (MPNST).
Metastatic colorectal cancer remains the second leading cause of cancer-related mortality globally, but treatment options are generally limited to RAS mutation status for anti-EGFR therapies. Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne developed a method to grow organoids from patient-derived tumor samples that achieved 83% accuracy in predicting patient responses to different therapies.
NZP UK Ltd. has divulged 3-azasteroid compounds reported to be useful for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, acute radiation syndrome and neurodegenerative disorders.
Researchers at Daegu-Gyeongbuk Medical Innovation Foundation and Korean Research Institute of Bioscience and Biotechnology have identified acetyl-CoA carboxylase (ACC) inhibitors reported to be useful for the treatment of liver cancer.
Synnovation Therapeutics Inc. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).
RSS
